Bolt Biotherapeutics (BOLT NASDAQ) stock market data APIs
$5.3098
-0.1(-1.9%)
as of September 15, 2025
Try our APIs with
free plan!
Bolt Biotherapeutics Financial Data Overview
Price chart is built with
Anychart
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Prev. Close
5.3098
Open
5.2068
High
5.3098
Low
5.1445
52 wk Range
4.59-14.36
Market Cap
10 211 K
Shares Outstanding
1 919 K
Revenue
4 167 K
EPS
-4.46
Beta
0.894
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Bolt Biotherapeutics data using free add-ons & libraries
Get Bolt Biotherapeutics Fundamental Data
Bolt Biotherapeutics Fundamental data includes:
- Net Revenue: 4 167 K
- EBITDA: -51 825 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-14
- EPS/Forecast: -0.31
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bolt Biotherapeutics News
New
Bolt Biotherapeutics GAAP EPS of -$4.46 beats by $1.99, revenue of $1.8M beats by $0.98M
* Bolt Biotherapeutics press release [https://seekingalpha.com/pr/20201891-bolt-biotherapeutics-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:BOLT [https://seekingalph...
Bolt Revenue Jumps 39 Percent in Q2
Key Points Revenue grew 38.5% year over year (GAAP basis) in Q2 2025 and was more than double analyst expectations, with GAAP revenue of $1.80 million exceeding the analyst estimate of $0.82 million ...
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Ca...
E-Hailing Market Competitive Landscape and Company Profiles Report 2025 | E-Hailing Market Forecast to Hit $170.11 Billion by 2029
Company Logo The e-hailing market is poised for significant growth, expanding from $67.65 billion in 2024 to a projected $170.11 billion in 2029 at a CAGR of 20.2%. Key drivers include increased smar...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
